Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 09 2021
Historique:
received: 24 08 2020
revised: 23 03 2021
accepted: 30 05 2021
pubmed: 26 6 2021
medline: 6 8 2021
entrez: 25 6 2021
Statut: ppublish

Résumé

Cytokine treatment with Interferon-alpha (IFN-α) represents a clinical model of immune associated depression, but it remains unclear if it is of the same entity as major depressive disorder (MDD). The study focuses on possible gender differences in IFN-α induced depression and effects of a pre-emptive antidepressant treatment. Data from 181 patients with chronic hepatitis C infection (cHC) without history of mental illnesses undergoing treatment with IFN-α 2a and ribavirin were re-analyzed for gender effects. Patients with a pre-emptive antidepressant therapy with Escitalopram (n = 90, verum group) to prevent IFN-induced depression were compared to patients who received placebo (n = 91). Depressive symptoms before and during HCV-treatment were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS), Beck's Depression Inventory (BDI) and the Hamilton Anxiety Rating Scale. We found significant differences regarding the incidence and severity of depressive symptoms between men and women for patients without antidepressant pre-treatment (placebo group). Significantly more women without pre-emptive antidepressant therapy suffered from clinically relevant depression (MADRS values ≥ 13, p = 0.041) and self-rated depressive symptoms (BDI ≥ 17, p = 0.024). Antidepressant pre-treatment showed comparable effects regarding the reduction of incidence and severity of depression in both women and men. Compared to MDD, IFN-alpha-induced depression in patients with cHC is also characterized by gender differences with an increased risk for women but no gender difference regarding the effects of an antidepressant pre-treatment is found. Our data strengthens the hypothesis that Interferon-induced depression serves as a clinical model for immune related depressive disorders.

Sections du résumé

BACKGROUND
Cytokine treatment with Interferon-alpha (IFN-α) represents a clinical model of immune associated depression, but it remains unclear if it is of the same entity as major depressive disorder (MDD). The study focuses on possible gender differences in IFN-α induced depression and effects of a pre-emptive antidepressant treatment.
METHODS
Data from 181 patients with chronic hepatitis C infection (cHC) without history of mental illnesses undergoing treatment with IFN-α 2a and ribavirin were re-analyzed for gender effects. Patients with a pre-emptive antidepressant therapy with Escitalopram (n = 90, verum group) to prevent IFN-induced depression were compared to patients who received placebo (n = 91). Depressive symptoms before and during HCV-treatment were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS), Beck's Depression Inventory (BDI) and the Hamilton Anxiety Rating Scale.
RESULTS
We found significant differences regarding the incidence and severity of depressive symptoms between men and women for patients without antidepressant pre-treatment (placebo group). Significantly more women without pre-emptive antidepressant therapy suffered from clinically relevant depression (MADRS values ≥ 13, p = 0.041) and self-rated depressive symptoms (BDI ≥ 17, p = 0.024). Antidepressant pre-treatment showed comparable effects regarding the reduction of incidence and severity of depression in both women and men.
CONCLUSIONS
Compared to MDD, IFN-alpha-induced depression in patients with cHC is also characterized by gender differences with an increased risk for women but no gender difference regarding the effects of an antidepressant pre-treatment is found. Our data strengthens the hypothesis that Interferon-induced depression serves as a clinical model for immune related depressive disorders.

Identifiants

pubmed: 34171555
pii: S0165-0327(21)00531-0
doi: 10.1016/j.jad.2021.05.087
pii:
doi:

Substances chimiques

Antiviral Agents 0
Cytokines 0
Interferon-alpha 0
Ribavirin 49717AWG6K

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

766-772

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Susanne Sarkar (S)

Department of Clinical Psychology and Psychotherapy, Universität Hamburg, Hamburg, Germany.

Jonas Kemper (J)

Department of Psychiatry, Psychotherapy, Psychosomatics and Addiction Medicine, Evang. Kliniken Essen-Mitte, Essen, Germany.

Rahul Sarkar (R)

Department of Psychiatry, Psychotherapy and Psychosomatics, Sana-Regio Elmshorn, Germany.

Loni Brants (L)

Department of Psychiatry and Psychotherapy, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Germany.

Astrid Friebe (A)

Praxis für Psychiatrie und Psychotherapie, Trödelmarkt, Nürnberg, Germany.

Ulrich Spengler (U)

Department of Internal Medicine I, Universitätsklinikum Bonn, Germany.

Thomas Schläpfer (T)

Division of Interventional Biological Psychiatry, Department of Psychiatry and Psychotherapy, University Hospital Freiburg, Germany.

Jens Reimer (J)

Zentrum für psychosoziale Medizin, Klinikum Bremen-Ost, Bremen, Germany.

Peter Buggisch (P)

Institute for Interdisciplinary Medicine, Asklepios-Clinic, St. Georg, Hamburg, Germany.

Johann Ockenga (J)

Department of Gastroenterology, Medizinische Klinik II, Klinikum Bremen-Mitte, Germany.

Ralph Link (R)

Medizinisches Versorgungszentrum, Gastroenterology and Hepatology, Offenburg, Germany.

Michael Rentrop (M)

Klinische Sozialpsychiatrie, kbo-Inn-Salzach-Klinikum Wasserburg am Inn, Gabersee, Germany.

Hans Weidenbach (H)

Department of Gastroenterology and Internal Medicine, Klinikum Mittelbaden, Baden Baden, Germany.

Gwendolyn Fromm (G)

Department of Psychiatry and Psychotherapy, Universitätsklinikum Giessen, Germany.

Klaus Lieb (K)

Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany.

Thomas F Baumert (TF)

Institute of Viral and Liver Disease, Laboratory of Excellence HepSYS, University of Strasbourg,France.

Thomas Discher (T)

Department of Internal Medicine II, Universitätsklinikum Giessen, Germany.

Stefan Zeuzem (S)

Department of Gastroenterology and Hepatology, Medizinische Klinik I, Goethe Universität, Frankfurt/Main, Germany.

Thomas Berg (T)

Division of Hepatology; Department of Oncology, Gastroenterology and Infectious Disease, Universitätsklinikum Leipzig, Germany.

Martin Schaefer (M)

Department of Clinical Psychology and Psychotherapy, Universität Hamburg, Hamburg, Germany; Department of Psychiatry and Psychotherapy, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Germany. Electronic address: m.schaefer@kem-med.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH